Session

PP 05 IBD (Posters)

COMPARATIVE EFFICACY OF SECOND-LINE THERAPIES IN ULCERATIVE COLITIS: A MONOCENTRIC EXPERIENCE FROM A TERTIARY REFERRAL CENTER
COMPARATIVE EFFICACY OF SECOND-LINE THERAPIES IN ULCERATIVE COLITIS: A MONOCENTRIC EXPERIENCE FROM A TERTIARY REFERRAL CENTER

PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL OF ANTI-TNF AGENTS IN THE MANAGEMENT OF CROHN’S DISEASE
PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM SURVIVAL OF ANTI-TNF AGENTS IN THE MANAGEMENT OF CROHN’S DISEASE

THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)
THE BURDEN OF BOWEL URGENCY IN ULCERATIVE COLITIS: A FRENCH MULTICENTRIC REAL-LIFE STUDY (THEFAR)

FATIGUE IS NOT RELATED TO SARCOPENIA IN CROHN'S DISEASE PATIENTS IN DEEP REMISSION
FATIGUE IS NOT RELATED TO SARCOPENIA IN CROHN'S DISEASE PATIENTS IN DEEP REMISSION

THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
THE ASSOCIATION OF ENDOSCOPIC AND HISTOLOGIC ENDPOINTS WITH FAECAL CALPROTECTIN AND C-REACTIVE PROTEIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB

COMPARATIVE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN ELDERLY AND YOUNGER PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARATIVE EFFICACY AND SAFETY OF BIOLOGIC THERAPIES IN ELDERLY AND YOUNGER PATIENTS WITH INFLAMMATORY BOWEL DISEASE

TRANSMURAL HEALING IS NOT ASSOCIATED WITH LESS DISABILITY THAN COMPLETE ENDOSCOPIC MUCOSAL HEALING: A PROSPECTIVE STUDY IN CROHN'S DISEASE PATIENT
TRANSMURAL HEALING IS NOT ASSOCIATED WITH LESS DISABILITY THAN COMPLETE ENDOSCOPIC MUCOSAL HEALING: A PROSPECTIVE STUDY IN CROHN'S DISEASE PATIENT

ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY
ULTRASOUND IS EFFECTIVE TO IDENTIFY MUCOSAL HEALING IN CROHN'S DISEASE PATIENTS : RESULTS OF A CROSS-SECTIONAL STUDY

MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
MATCHING-ADJUSTED INDIRECT COMPARISON OF UPADACITINIB VERSUS USTEKINUMAB ON ENDOSCOPIC OUTCOMES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

INTESTINAL ULTRASOUND COMBINED TO FECAL CALPROTECTIN IS EFFECTIVE TO PREDICT ENDOSCOPIC MUCOSAL HEALING IN ULCERATIVE COLITIS: A CROSS-SECTIONAL STUDY
INTESTINAL ULTRASOUND COMBINED TO FECAL CALPROTECTIN IS EFFECTIVE TO PREDICT ENDOSCOPIC MUCOSAL HEALING IN ULCERATIVE COLITIS: A CROSS-SECTIONAL STUDY

SAFETY OF VEDOLIZUMAB, USTEKINUMAB AND TNF INHIBITORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY
SAFETY OF VEDOLIZUMAB, USTEKINUMAB AND TNF INHIBITORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE MONOCENTRIC COHORT STUDY

ISOLATED ANASTOMOTIC LINE ULCERATIONS ARE ASSOCIATED WITH A HIGHER RISK OF POSTOPERATIVE RECURRENCE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING ILEOCECAL RESECTION AND A DIFFERENTIAL MUCOSA-ASSOCIATED MICROBIOME COMPOSITION
ISOLATED ANASTOMOTIC LINE ULCERATIONS ARE ASSOCIATED WITH A HIGHER RISK OF POSTOPERATIVE RECURRENCE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING ILEOCECAL RESECTION AND A DIFFERENTIAL MUCOSA-ASSOCIATED MICROBIOME COMPOSITION

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE
THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB IN BIO-NAÏVE AND BIO-EXPERIENCED PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD
INFLIXIMAB BIOSIMILAR SWITCH IS SAFE AND EFFECTIVE, IT DOES NOT HAVE MAJOR PSYCHOLOGICAL IMPLICATIONS AND DOES NOT AFFET PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH IBD

THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TNF INHIBITORS IN BIO-NAÏVE PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE
THE COMPARATIVE EFFECTIVENESS OF VEDOLIZUMAB AND TNF INHIBITORS IN BIO-NAÏVE PATIENTS WITH IBD: RESULTS FROM A REAL-WORLD EXPERIENCE AT A BELGIAN TERTIARY CENTRE

ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS
ACHIEVEMENT OF LONG-TERM TREATMENT GOALS WITH UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF INDUCTION AND MAINTENANCE PHASE 3 TRIALS

CORRELATION OF THE IBD DISK WITH INTESTINAL ULTRASOUND IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
CORRELATION OF THE IBD DISK WITH INTESTINAL ULTRASOUND IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS
MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS

FILGOTINIB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: AN EARLY REAL-WORLD UK TERTIARY CENTRE EXPERIENCE
FILGOTINIB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS: AN EARLY REAL-WORLD UK TERTIARY CENTRE EXPERIENCE

SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

PP 05 IBD (Posters)

Item 541 - 560 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28
29 30 31 32 33 34 35 36 37 38 39 40 41 42